Mingjun Li
Impact in
-
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
-
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
Papers in
-
- Lung Cancer Treatments and Mutations 3
- Co-authors
- Xingya Li (2 shared papers)Ningning Yan (2 shared papers)Wengang Wang (2 shared papers)Yanru Qin (2 shared papers)Xiaofei Zhang (1 shared paper)Benling Xu (2 shared papers)Yongxu Jia (2 shared papers)Huijie Fan (2 shared papers)
- Journals
- International Journal of Molecular Medicine (1 paper)Journal of Cellular Biochemistry (1 paper)Cancer Cell International (1 paper)JAMA (1 paper)The Lancet Respiratory Medicine (1 paper)
- Partner nations
- China
In The Last Decade
Mingjun Li
14 papers receiving 348 citations
Mingjun Li's Hit Papers
Peers
Comparison fields: 5 of 58
- Oncology 114
- Cancer Research 60
- Pulmonary and Respiratory Medicine 84
- Molecular Biology 145
- Immunology 31
Countries citing papers authored by Mingjun Li
This map shows the geographic impact of Mingjun Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mingjun Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mingjun Li more than expected).
Fields of papers citing papers by Mingjun Li
This network shows the impact of papers produced by Mingjun Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mingjun Li. The network helps show where Mingjun Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Mingjun Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant Hit paper breakdown → | 2024 | 115 |
| 2 | 2022 | 52 | |
| 3 | 2015 | 31 | |
| 4 | 2017 | 30 | |
| 5 | 2020 | 26 | |
| 6 | 2021 | 24 | |
| 7 | 2017 | 18 | |
| 8 | 2022 | 18 | |
| 9 | 2014 | 17 | |
| 10 | 2025 | 8 | |
| 11 | 2012 | 7 | |
| 12 | 2024 | 6 | |
| 13 | 2024 | 2 | |
| 14 | 2025 | 1 |
About Mingjun Li
Mingjun Li is a scholar working on Pharmacology, Pulmonary and Respiratory Medicine, Molecular Biology, Immunology and Oncology, having authored 14 papers that have together received 355 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (3 papers), RNA modifications and cancer (2 papers), Bone Metabolism and Diseases (2 papers), Thermal Expansion and Ionic Conductivity (1 paper), Biomarkers in Disease Mechanisms (1 paper), Nanoparticle-Based Drug Delivery (1 paper), Macrophage Migration Inhibitory Factor (1 paper) and Adipokines, Inflammation, and Metabolic Diseases (1 paper). The work is most often cited by research in Oncology (114 citations), Cancer Research (60 citations), Pulmonary and Respiratory Medicine (84 citations), Molecular Biology (145 citations) and Immunology (31 citations). Mingjun Li has collaborated with scholars based in China. Frequent co-authors include Xingya Li, Ningning Yan, Wengang Wang, Yanru Qin, Xiaofei Zhang, Benling Xu, Yongxu Jia, Huijie Fan, Xiaofei Zhang and Mingzhi Zhang. Their work appears in journals such as International Journal of Molecular Medicine, Journal of Cellular Biochemistry, Cancer Cell International, JAMA and The Lancet Respiratory Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.